These compounds may be acting through the estrogen β receptor (EβR) and the PI3 K/Akt/mTOR signaling pathway, previously shown to stimulate OL differentiation and remyelination in vivo in demyelinating animal models of MS [14–18]. Here, MTOR is linked to myeloid sarcoma.